Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
CNBC Top News·2d·Media
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
ChannelsstocksCountriesusaCategoriesmergers-acquisitions
Open original source ↗Published
5/26/2026, 3:38:08 PM
Fetched
5/26/2026, 4:08:05 PM
Confidence
60 / 100
Relevance
44 / 100
Trust
media · 60/100
Language
en